To identify which NSCLCs would be sensitive to SAH-JGZ4 treatment, three more NSCLC cell lines with different expression level of TRIB3 and EGFR (shown in Fig.1a) were tested using in vivo models. This evidence concerns the gene TRIB3 and non-small cell lung carcinoma.